COMMUNIQUÉS West-GlobeNewswire

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
10/05/2024
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of [...]
Healthcare Integrated Technologies, Inc. Welcomes Ryan Holland to its Board of Directors
10/05/2024
Knoxville, Tennessee, May 10, 2024 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies, Inc. (“HiTC”), a pioneer in developing advanced healthcare technology solutions, is excited to announce the appointment of Ryan [...]
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
10/05/2024
SOLANA BEACH, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
10/05/2024
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for [...]
Optimi Health Provides Corporate Update
10/05/2024
VANCOUVER, British Columbia, May 10, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), a leading Health Canada licensed GMP psychedelics pharmaceutical [...]
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
10/05/2024
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first [...]
Curia et Carterra coorganisent un symposium sur les produits biologiques pour encourager la recherche en biotechnologie dans le nord-ouest du Pacifique
10/05/2024
ALBANY, New York et SALT LAKE CITY, 10 mai 2024 (GLOBE NEWSWIRE) -- Curia, une organisation de premier plan du domaine de la recherche, du développement et de la fabrication sous contrat, et Carterra Inc., leader [...]
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
10/05/2024
BERKELEY HEIGHTS, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
10/05/2024
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201 - Clinically meaningful tumor reduction observed at [...]
iTeos Therapeutics Announces $120 Million Registered Direct Offering
10/05/2024
- Led by existing investors RA Capital Management and Boxer Capital - Purchase price of $17.50 represents a premium of approximately 44% to last close - Further strengthens balance sheet with pro forma cash position of [...]
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
10/05/2024
The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the " [...]
Smart for Life to Attend Vitafoods Europe 2024: Positioned to Identify Strategic Partnerships and Potential Acquisitions
10/05/2024
Renowned Industry Leader and Smart for Life Board Member Heather Granato to Speak at Nutraceutical Event in Geneva, Switzerland MIAMI, May 10, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for [...]
Mobile-health Network Solutions Expands Services to Malaysia
10/05/2024
SINGAPORE, May 10, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today announced the establishment of a subsidiary in [...]
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
10/05/2024
BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
10/05/2024
-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical [...]
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
10/05/2024
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of [...]
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
10/05/2024
The FDA Assigned Goal Date is October 29, 2024 TORONTO, May 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today [...]
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
10/05/2024
BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of [...]
Ocugen to Present at May 2024 Investor Conferences
10/05/2024
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]

Pages